1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Scott, A.
Pantoja-Uceda, D.
Koshiba, S.
Inoue, M.
Kigawa, T.
Terada, T.
Shirouzu, M.
Tanaka, A.
Sugano, S.
Yokoyama, S.
Guntert, P.
RIKEN Structural Genomics/Proteomics Initiative (RSGI)
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
NE
J.Biomol.NMR
JBNME9
0800
0925-2738
31
357
361
10.1007/s10858-005-0946-6
15929003
Solution structure of the Src homology 2 domain from the human feline sarcoma oncogene Fes
2005
To be Published
0353
NMR assignment of the SH2 domain from the human feline sarcoma oncogene FES
10.2210/pdb1wqu/pdb
pdb_00001wqu
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
12506.106
Proto-oncogene tyrosine-protein kinase FES/FPS
2.7.1.112
SH2 domain
1
man
polymer
C-FES
no
no
GSSGSSGEVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPS
IPLLIDHLLSTQQPLTKKSGVVLHRAVPSGPSSG
GSSGSSGEVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPS
IPLLIDHLLSTQQPLTKKSGVVLHRAVPSGPSSG
A
hss001002011.2
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
cell-free protein synthesis
9606
Homo sapiens
plasmid
p040524-01
RIKEN Structural Genomics/Proteomics Initiative
RSGI
database_2
pdbx_nmr_spectrometer
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2005-06-14
1
1
2008-04-30
1
2
2011-07-13
1
3
2022-03-02
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_spectrometer.model
_struct_ref_seq_dif.details
Y
PDBJ
Y
PDBJ
2004-10-02
REL
structures with the least restraint violations
100
20
3D_13C-separated_NOESY
3D_15N-separated_NOESY
7.0
AMBIENT
298
K
automated NOESY assignment, torsion angle dynamics, energy minimization
1
closest to the average
1.2mM uniformly 13C and 15N labeled protein; 20mM Tris-HCl buffer; 100mM NaCl; 1mM dithiothreitol; 0.02% NaN3
90% H2O/10% D2O
Delaglio, F.
processing
NMRPipe
2.1
Johnson, B.
data analysis
NMRView
5.0.4
Guntert, P.
structure solution
CYANA
2.0.32
Koradi, R., Billeter, M., Guntert, P.
refinement
OPALp
1.3
600
Bruker
DRX
800
Bruker
AVANCE
GLY
1
n
1
GLY
1
A
SER
2
n
2
SER
2
A
SER
3
n
3
SER
3
A
GLY
4
n
4
GLY
4
A
SER
5
n
5
SER
5
A
SER
6
n
6
SER
6
A
GLY
7
n
7
GLY
7
A
GLU
8
n
8
GLU
8
A
VAL
9
n
9
VAL
9
A
GLN
10
n
10
GLN
10
A
LYS
11
n
11
LYS
11
A
PRO
12
n
12
PRO
12
A
LEU
13
n
13
LEU
13
A
HIS
14
n
14
HIS
14
A
GLU
15
n
15
GLU
15
A
GLN
16
n
16
GLN
16
A
LEU
17
n
17
LEU
17
A
TRP
18
n
18
TRP
18
A
TYR
19
n
19
TYR
19
A
HIS
20
n
20
HIS
20
A
GLY
21
n
21
GLY
21
A
ALA
22
n
22
ALA
22
A
ILE
23
n
23
ILE
23
A
PRO
24
n
24
PRO
24
A
ARG
25
n
25
ARG
25
A
ALA
26
n
26
ALA
26
A
GLU
27
n
27
GLU
27
A
VAL
28
n
28
VAL
28
A
ALA
29
n
29
ALA
29
A
GLU
30
n
30
GLU
30
A
LEU
31
n
31
LEU
31
A
LEU
32
n
32
LEU
32
A
VAL
33
n
33
VAL
33
A
HIS
34
n
34
HIS
34
A
SER
35
n
35
SER
35
A
GLY
36
n
36
GLY
36
A
ASP
37
n
37
ASP
37
A
PHE
38
n
38
PHE
38
A
LEU
39
n
39
LEU
39
A
VAL
40
n
40
VAL
40
A
ARG
41
n
41
ARG
41
A
GLU
42
n
42
GLU
42
A
SER
43
n
43
SER
43
A
GLN
44
n
44
GLN
44
A
GLY
45
n
45
GLY
45
A
LYS
46
n
46
LYS
46
A
GLN
47
n
47
GLN
47
A
GLU
48
n
48
GLU
48
A
TYR
49
n
49
TYR
49
A
VAL
50
n
50
VAL
50
A
LEU
51
n
51
LEU
51
A
SER
52
n
52
SER
52
A
VAL
53
n
53
VAL
53
A
LEU
54
n
54
LEU
54
A
TRP
55
n
55
TRP
55
A
ASP
56
n
56
ASP
56
A
GLY
57
n
57
GLY
57
A
LEU
58
n
58
LEU
58
A
PRO
59
n
59
PRO
59
A
ARG
60
n
60
ARG
60
A
HIS
61
n
61
HIS
61
A
PHE
62
n
62
PHE
62
A
ILE
63
n
63
ILE
63
A
ILE
64
n
64
ILE
64
A
GLN
65
n
65
GLN
65
A
SER
66
n
66
SER
66
A
LEU
67
n
67
LEU
67
A
ASP
68
n
68
ASP
68
A
ASN
69
n
69
ASN
69
A
LEU
70
n
70
LEU
70
A
TYR
71
n
71
TYR
71
A
ARG
72
n
72
ARG
72
A
LEU
73
n
73
LEU
73
A
GLU
74
n
74
GLU
74
A
GLY
75
n
75
GLY
75
A
GLU
76
n
76
GLU
76
A
GLY
77
n
77
GLY
77
A
PHE
78
n
78
PHE
78
A
PRO
79
n
79
PRO
79
A
SER
80
n
80
SER
80
A
ILE
81
n
81
ILE
81
A
PRO
82
n
82
PRO
82
A
LEU
83
n
83
LEU
83
A
LEU
84
n
84
LEU
84
A
ILE
85
n
85
ILE
85
A
ASP
86
n
86
ASP
86
A
HIS
87
n
87
HIS
87
A
LEU
88
n
88
LEU
88
A
LEU
89
n
89
LEU
89
A
SER
90
n
90
SER
90
A
THR
91
n
91
THR
91
A
GLN
92
n
92
GLN
92
A
GLN
93
n
93
GLN
93
A
PRO
94
n
94
PRO
94
A
LEU
95
n
95
LEU
95
A
THR
96
n
96
THR
96
A
LYS
97
n
97
LYS
97
A
LYS
98
n
98
LYS
98
A
SER
99
n
99
SER
99
A
GLY
100
n
100
GLY
100
A
VAL
101
n
101
VAL
101
A
VAL
102
n
102
VAL
102
A
LEU
103
n
103
LEU
103
A
HIS
104
n
104
HIS
104
A
ARG
105
n
105
ARG
105
A
ALA
106
n
106
ALA
106
A
VAL
107
n
107
VAL
107
A
PRO
108
n
108
PRO
108
A
SER
109
n
109
SER
109
A
GLY
110
n
110
GLY
110
A
PRO
111
n
111
PRO
111
A
SER
112
n
112
SER
112
A
SER
113
n
113
SER
113
A
GLY
114
n
114
GLY
114
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
GLY
21
A
N
GLY
21
A
O
GLU
42
A
O
GLU
42
A
N
LEU
39
A
N
LEU
39
A
O
SER
52
A
O
SER
52
A
N
LEU
51
A
N
LEU
51
A
O
PHE
62
A
O
PHE
62
A
N
GLY
21
A
N
GLY
21
A
O
GLU
42
A
O
GLU
42
A
N
PHE
38
A
N
PHE
38
A
O
ARG
105
A
O
ARG
105
A
N
GLN
65
A
N
GLN
65
A
O
ARG
72
A
O
ARG
72
6
A
A
OE1
HG1
GLU
THR
74
96
1.57
2
A
TYR
19
0.077
SIDE CHAIN
2
A
ARG
72
0.089
SIDE CHAIN
2
A
ARG
105
0.086
SIDE CHAIN
3
A
ARG
72
0.123
SIDE CHAIN
5
A
TYR
19
0.088
SIDE CHAIN
5
A
ARG
60
0.088
SIDE CHAIN
7
A
ARG
105
0.081
SIDE CHAIN
12
A
ARG
41
0.079
SIDE CHAIN
15
A
ARG
25
0.091
SIDE CHAIN
15
A
ARG
105
0.100
SIDE CHAIN
18
A
ARG
41
0.092
SIDE CHAIN
20
A
ARG
41
0.094
SIDE CHAIN
4
3.18
0.50
120.30
123.48
A
A
A
NE
CZ
NH1
ARG
ARG
ARG
72
72
72
N
1
A
ALA
22
-74.92
26.89
1
A
ASP
56
56.07
8.02
1
A
LEU
67
-153.89
-61.05
1
A
ASP
68
-78.23
30.65
1
A
LEU
73
-142.71
-33.13
1
A
GLU
74
-156.93
-31.20
1
A
SER
99
-134.53
-39.44
2
A
VAL
33
-131.12
-31.59
2
A
GLN
47
-75.97
37.41
2
A
ILE
63
-67.98
97.02
2
A
ILE
64
-56.38
108.68
2
A
GLU
74
-155.57
-56.48
3
A
HIS
14
-65.60
0.53
3
A
ALA
22
-76.75
25.30
3
A
GLN
47
57.85
12.70
3
A
ASP
56
49.24
18.72
3
A
ASN
69
70.73
-5.03
3
A
LEU
73
-131.27
-36.28
3
A
GLU
74
-159.69
-20.35
4
A
LEU
73
-142.80
-49.39
5
A
ALA
22
-71.82
43.03
5
A
TRP
55
-152.56
-85.89
5
A
ASP
56
-79.24
23.85
5
A
PRO
59
-68.62
92.66
5
A
LEU
67
-130.09
-81.06
5
A
ASP
68
-75.73
37.69
6
A
SER
3
-108.46
-151.60
6
A
ALA
22
38.89
18.91
6
A
ASP
56
55.70
2.00
6
A
ASP
68
49.95
22.96
6
A
LEU
73
-125.26
-78.70
6
A
THR
96
-177.53
141.89
7
A
VAL
33
-136.21
-35.88
7
A
GLN
44
-41.77
107.51
7
A
TRP
55
-149.20
-63.35
7
A
ASP
56
-107.24
42.53
7
A
LEU
67
-150.28
-5.09
7
A
LEU
73
-150.90
-32.59
7
A
GLU
74
-113.20
-71.81
7
A
SER
113
-55.04
102.72
8
A
SER
3
-75.45
-169.58
8
A
ALA
22
-66.91
26.68
8
A
ASP
68
56.63
18.00
8
A
ASN
69
91.90
2.99
8
A
LEU
73
-127.20
-83.90
8
A
PRO
111
-68.26
38.43
9
A
SER
2
-61.04
4.27
9
A
ALA
22
46.66
11.40
9
A
LYS
46
-65.45
24.23
9
A
TRP
55
-145.30
-97.88
10
A
SER
3
-104.67
-90.59
10
A
SER
5
-51.28
104.42
10
A
GLN
47
-73.37
36.26
10
A
TRP
55
-150.42
-36.36
10
A
LEU
67
-127.77
-89.76
10
A
ASN
69
64.97
-3.92
10
A
GLU
74
60.01
-6.96
11
A
ALA
22
35.49
17.89
11
A
VAL
33
-142.70
-29.45
11
A
GLN
47
-96.75
40.55
11
A
LEU
67
-130.48
-61.82
11
A
ASP
68
-82.77
43.75
11
A
ASN
69
61.48
-1.03
11
A
LEU
73
-130.03
-53.45
11
A
GLU
74
-141.12
-39.71
11
A
LYS
98
-66.57
4.80
12
A
SER
5
-148.24
20.79
12
A
HIS
14
-67.64
0.02
12
A
ALA
22
-69.11
29.64
12
A
ASP
56
55.73
11.29
12
A
LEU
73
-144.58
-33.14
12
A
GLU
74
-150.80
-61.06
12
A
LYS
98
-44.65
-76.17
12
A
PRO
111
-80.49
44.51
13
A
SER
2
-116.72
-83.65
13
A
ALA
22
-69.99
27.70
13
A
VAL
33
-131.83
-30.25
13
A
GLN
44
-70.23
26.40
13
A
LEU
73
-131.32
-44.33
13
A
GLU
74
-139.32
-50.80
13
A
LYS
98
-54.68
-74.50
13
A
SER
112
-55.75
171.96
14
A
ALA
22
-67.02
18.58
14
A
GLN
44
-66.34
22.49
14
A
TRP
55
-141.73
-51.45
14
A
LEU
67
-136.89
-68.59
14
A
ASP
68
-84.84
34.47
14
A
GLU
74
-142.95
-14.95
15
A
GLN
44
-20.60
101.88
15
A
TRP
55
-142.10
-60.61
15
A
LEU
67
-109.64
-76.25
15
A
ASP
68
-93.81
31.61
15
A
ASN
69
79.13
-8.86
15
A
PRO
111
-69.08
15.74
16
A
SER
3
-142.88
-156.72
16
A
SER
5
-68.85
68.27
16
A
ILE
23
-38.46
134.79
16
A
GLN
44
-3.77
-90.75
16
A
GLN
47
44.20
28.13
16
A
LEU
67
-160.66
-61.12
16
A
ASP
68
-97.60
56.18
16
A
ASN
69
59.23
-0.91
16
A
GLU
74
58.12
18.73
17
A
SER
3
39.97
54.81
17
A
SER
5
176.01
-176.07
17
A
ALA
22
42.93
20.10
17
A
GLU
48
-162.08
114.59
17
A
ASP
56
56.65
1.83
17
A
PRO
59
-68.84
99.87
17
A
LEU
73
-134.00
-30.47
17
A
GLU
74
-156.78
-67.36
17
A
ARG
105
-172.55
146.26
18
A
SER
6
-72.52
25.98
18
A
ALA
22
-78.89
49.08
18
A
VAL
33
-138.57
-30.76
18
A
GLN
47
-73.83
38.15
18
A
LEU
67
-147.64
-77.61
18
A
ASP
68
-73.05
29.12
18
A
ARG
72
155.63
-154.66
18
A
LEU
73
-123.61
-79.51
19
A
SER
5
-57.48
105.45
19
A
SER
43
-68.63
-170.09
19
A
PRO
59
-68.35
94.45
19
A
LEU
67
-131.48
-78.70
19
A
ASP
68
-81.43
35.68
19
A
LEU
73
-121.56
-66.96
20
A
ALA
22
-75.79
41.14
20
A
GLN
44
-47.78
106.08
20
A
GLN
47
-119.51
68.98
20
A
LEU
67
-132.61
-57.66
20
A
LEU
73
-134.36
-39.18
20
A
GLU
74
-136.13
-53.80
Solution structure of the human FES SH2 domain
1
N
N
A
GLY
7
A
GLY
7
HELX_P
A
LYS
11
A
LYS
11
5
1
5
A
PRO
12
A
PRO
12
HELX_P
A
GLN
16
A
GLN
16
5
2
5
A
PRO
24
A
PRO
24
HELX_P
A
GLU
30
A
GLU
30
1
3
7
A
SER
80
A
SER
80
HELX_P
A
GLN
92
A
GLN
92
1
4
13
TRANSFERASE
SH2 domain, FES, feline sarcoma oncogene, structural genomics, RIKEN Structural Genomics/Proteomics Initiative, RSGI, Transferase
FES_HUMAN
UNP
1
450
P07332
EVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPSIPLLIDH
LLSTQQPLTKKSGVVLHRAVP
450
550
1WQU
8
108
P07332
A
1
8
108
1
cloning artifact
GLY
1
1WQU
A
P07332
UNP
1
1
cloning artifact
SER
2
1WQU
A
P07332
UNP
2
1
cloning artifact
SER
3
1WQU
A
P07332
UNP
3
1
cloning artifact
GLY
4
1WQU
A
P07332
UNP
4
1
cloning artifact
SER
5
1WQU
A
P07332
UNP
5
1
cloning artifact
SER
6
1WQU
A
P07332
UNP
6
1
cloning artifact
GLY
7
1WQU
A
P07332
UNP
7
1
cloning artifact
SER
109
1WQU
A
P07332
UNP
109
1
cloning artifact
GLY
110
1WQU
A
P07332
UNP
110
1
cloning artifact
PRO
111
1WQU
A
P07332
UNP
111
1
cloning artifact
SER
112
1WQU
A
P07332
UNP
112
1
cloning artifact
SER
113
1WQU
A
P07332
UNP
113
1
cloning artifact
GLY
114
1WQU
A
P07332
UNP
114
4
3
2
parallel
anti-parallel
anti-parallel
parallel
parallel
anti-parallel
A
TYR
19
A
TYR
19
A
GLY
21
A
GLY
21
A
ASP
37
A
ASP
37
A
GLU
42
A
GLU
42
A
TYR
49
A
TYR
49
A
TRP
55
A
TRP
55
A
LEU
58
A
LEU
58
A
ILE
63
A
ILE
63
A
TYR
19
A
TYR
19
A
GLY
21
A
GLY
21
A
ASP
37
A
ASP
37
A
GLU
42
A
GLU
42
A
ARG
105
A
ARG
105
A
ALA
106
A
ALA
106
A
GLN
65
A
GLN
65
A
SER
66
A
SER
66
A
TYR
71
A
TYR
71
A
ARG
72
A
ARG
72
1
P 1